论文部分内容阅读
目的通过体外实验探讨贝伐单抗(bevacizumab)对人肝癌细胞HepG2增殖的抑制作用及可能的分子机制。方法MTT法检测贝伐单抗对肝癌细胞增殖的抑制作用;流式细胞仪检测细胞凋亡;RT-PCR分析肝癌细胞株VEGF、Flt-1、KDR mRNA表达量的变化。结果不同质量浓度的贝伐单抗对肝癌细胞株HepG2的增殖有抑制作用;贝伐单抗可诱导肝癌细胞株HepG2的凋亡;贝伐单抗作用于肝癌细胞株HepG2后,其VEGF、KDR mRNA表达量均减少。结论贝伐单抗可能通过阻断VEGF的促增殖作用而抑制HepG2细胞增殖。
Objective To investigate the inhibitory effect of bevacizumab on the proliferation of human hepatoma HepG2 cells and its possible molecular mechanism in vitro. Methods The inhibitory effect of bevacizumab on the proliferation of hepatoma cells was detected by MTT assay. The apoptosis of hepatocellular carcinoma cells was detected by flow cytometry. The expression of VEGF, Flt-1 and KDR mRNA was detected by RT-PCR. Results The different concentrations of bevacizumab could inhibit the proliferation of HepG2 cells. Bevacizumab induced the apoptosis of HepG2 cells. After treated with bevacizumab, the VEGF and KDR mRNA expression decreased. Conclusion Bevacizumab may inhibit the proliferation of HepG2 cells by blocking the proliferation of VEGF.